T-peptide immunomodulator for treating sepsis

A sepsis, regulatory technology, applied in the field of biomedicine, can solve problems such as decreased quality of life, secondary infection of latent virus, and increased mortality

Active Publication Date: 2014-08-06
FIRST HOSPITAL AFFILIATED TO GENERAL HOSPITAL OF PLA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The specific manifestation is that pathogens cannot be cleared, and it is easy to cause secondary infection and resurrection of latent virus, etc., and even exist for a period of time after the recovery of sepsis patients, resulting in a decline in quality of life and an increase in mortality after discharge [Winters BD, Eberlein M, Leung J, et al. Long-term mortality and quality of life in sepsis: a systematic review. CritCare Med, 2010, 38(5): 1276-1283]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • T-peptide immunomodulator for treating sepsis
  • T-peptide immunomodulator for treating sepsis
  • T-peptide immunomodulator for treating sepsis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1: Effect of T peptide on survival rate of mouse sepsis model

[0060] 1. Experimental animals and main reagents

[0061] Male BALB / c mice, 6-8w, 20+2g, were purchased from the Institute of Experimental Animals, Chinese Academy of Medical Sciences (animal certificate number: SCXK Beijing 2009-0007). Adaptive feeding for 1 week, free access to food and water, room temperature 25°C, 12h circadian rhythm.

[0062] Ketamine Hydrochloride Injection (Shanghai First Biochemical Pharmaceutical Company, China): Sumianxin II Injection (developed by Military Veterinary Research Institute, Academy of Military Medical Sciences, China): 0.9% normal saline (Shandong Luxin Pharmaceutical Group, China) by volume The ratio is 2:2.5:4.5. T-peptide: 1mg / cartridge, ①dissolve 4mg T-peptide in 10ml 0.9% normal saline, mix well, and use it in the 4mg / kg group; kg group; ③Take 2.5ml of the solution in ②, dilute to 10ml, and use it in the 0.25mg / kg group. The corresponding volume of ...

Embodiment 2

[0072] Example 2: Effect of T peptide on the activity of effector T lymphocytes

[0073] 1. Experimental animals and main reagents

[0074] Male BALB / c mice, 6-8w, 20±2g, were purchased from the Institute of Experimental Animals, Chinese Academy of Medical Sciences (animal certificate number: SCXK Beijing 2009-0007). Adaptive feeding for 1 week, free access to food and water, room temperature 25°C, 12h circadian rhythm.

[0075] T-peptide: 1 mg / cartridge, ① Dissolve 1 mg of T-peptide in RPMI-1640 medium (Beijing Suo Lai Bao Company, China) containing 10% fetal bovine serum (FBS, Hyclone Company, USA), mix well, and use In the 100μg / ml group; ②take 100μl of the solution of ①, dilute to 1ml, and use it in the 10μg / ml group; ③take 100μl of the solution of ②, dilute to 1ml, and use it in the 1μg / ml group. According to the needs of each group, use RPMI-1640 medium containing 10% fetal bovine serum to further dilute to the required concentration.

[0076] Purified anti-mouse-CD3 / ...

Embodiment 3

[0090] Example 3: Effect of T peptide on regulatory T cell activity

[0091] 1. Experimental animals and main reagents

[0092] Male BALB / c mice, 6-8w, 20±2g, were purchased from the Institute of Experimental Animals, Chinese Academy of Medical Sciences (animal certificate number: SCXK Beijing 2009-0007). Adaptive feeding for 1 week, free access to food and water, room temperature 25°C, 12h circadian rhythm.

[0093] T-peptide: 1mg / branch, 1. 1mg T-peptide is dissolved in containing 10% fetal bovine serum (FBS, Hyclone Company, U.S.A.) In the RPMI-1640 medium (Beijing Suolaibao Company, China), fully mix, For the 100μg / ml group; ②take 100μl of the solution of ①, dilute to 1ml, and use it for the 10μg / ml group; ③take 100μl of the solution of ②, dilute to 1ml, and use it for the 1μg / ml group. According to the needs of each group, use RPMI-1640 medium containing 10% fetal bovine serum to further dilute to the required concentration.

[0094] Purified anti-mouse-CD3 / CD28: eBios...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a T-peptide immunomodulator for treating sepsis. The immunomodulator adopts the structure of (Thr-Lys-Pro-Arg-AAN)4-(Lys-AAN)2-Lys-AAN, wherein N is a natural number. According to the immunomodulator, through animal experiment researches, the fact that T-peptide has functions of modulating proliferation and secretion of effector T cells and can relieve the negative immunoregulationeffect of regulatory T cells through combination of Nrp-1 (neuropilin-1) of surface molecules of the regulatory T cells is discovered. The T-peptide can relieve the immunosuppression state caused by the sepsis through the mechanism, particularly the cellular immunosuppression, so that the survival rate of sepsis mice can be increased, sepsis symptoms can be improved, and the T-peptide immunomodulator can be used for treating the sepsis.

Description

technical field [0001] The present invention relates to the technical field of biomedicine, in particular to T-peptides and applications thereof, more specifically, to the application of T-peptides in the preparation of drugs for the treatment of sepsis, wherein the T-peptides negatively regulate immune regulation by inhibiting regulatory T cells , Relieve the mechanism of cellular immunosuppression, increase the survival rate of sepsis organisms and improve the symptoms of sepsis. Background technique [0002] Sepsis is a systemic inflammatory response syndrome induced by infection. Sepsis is not simply an uncontrolled inflammatory response, but also severe and progressive immunosuppression, especially cellular immunosuppression. The specific manifestation is that pathogens cannot be cleared, and it is easy to cause secondary infection and resurrection of latent virus, etc., and even exist for a period of time after the recovery of sepsis patients, resulting in a decline i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(China)
IPC IPC(8): A61K38/16A61P29/00A61P37/04
Inventor姚咏明高玉雷祝筱梅韩苏
OwnerFIRST HOSPITAL AFFILIATED TO GENERAL HOSPITAL OF PLA